Mainboard
IPO ·
BSE, NSE
Sai Parenteral's Ltd
Listed
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.
Issue details
Price band
₹372 – ₹392
Face value
₹5
Lot size
38 shares
Minimum investment
₹14,896
Issue size
₹408.79 Cr
Fresh issue
₹285.00 Cr
Offer for sale
₹123.79 Cr
Issue type
Book Built
Exchange
BSE, NSE
Key dates
Opens
24 Mar 2026
Closes
27 Mar 2026
UPI mandate cut-off
5:00 PM on 27 Mar 2026
Allotment
30 Mar 2026
Refunds
1 Apr 2026
Shares in demat
1 Apr 2026
Listing
2 Apr 2026
Subscription and listing
Subscription
1.08x
Listing price
₹400
Registrar
Bigshare Services Pvt Ltd
Lead manager
Arihant Capital Markets
Subscription by category
Total
1.08x
Total applications
7,589
Anchor investors
Amount raised
₹122.64 Cr
Bid date
23 Mar 2026
50% lock-in ends
28 Apr 2026
Rest lock-in ends
27 Jun 2026
Listing day
Issue price
₹392
Open
₹400.00
High
₹416.00
Low
₹400.00
Day close
₹405.70
Listing gain at open
+2.04%
Issue structure
Shares reserved per category and share of the total issue
QIB Shares Offered
52,14,143
50.00%
Anchor Investor Shares Offered
31,28,485
30.00%
QIB (Ex. Anchor) Shares Offered
20,85,658
20.00%
NII Shares Offered
15,64,244
15.00%
bNII > ₹10L
10,42,829
10.00%
sNII < ₹10L
5,21,415
5.00%
Retail Shares Offered
36,49,901
35.00%
Total Shares Offered
1,04,28,288
100.00%
Finaccle’s quick read
Avoid
FY25 income up 6%, PAT up 71%, ROE 5.13%, post-issue P/E 111.68x.
A rules-based screen of growth, margins, debt and valuation, built from the offer document and data on Chittorgarh.com. It is for information only and is not investment advice or a recommendation to buy or sell. Read the RHP and speak to a SEBI-registered adviser before you apply.
About the company
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets. The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology.
Founded
Promoters
Promoter holding
Financial performance
Period
PAT
ROE
5.13%
ROCE
9.28%
Debt / equity
—
PAT margin
8.93%
P/E post issue
111.68
Market cap
₹1,731.83 Cr
Use of IPO money
Capacity expansion and upgradation of manufacturing facilities
₹110.80 Cr
Establishment of a new R&D Centre;
₹18.02 Cr
Repayment / prepayment of certain outstanding borrowings
₹14.30 Cr
Working capital requirements
₹33.00 Cr
Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (A
₹35.64 Cr
General corporate purposes
₹44.74 Cr
Issue Expenses
₹40.84 Cr
Strengths
✓
PAT up 71% in FY25 to ₹14.43 Cr
Risks to watch
!
Rich valuation: post-issue P/E of 111.68x
!
Modest PAT margin of 8.93%
!
30% of the issue is an offer for sale by existing shareholders
Planning to take your own company public?
Every listing on this page started with a growing business that got its numbers, governance and paperwork ready for investors. If you are a promoter weighing an SME or main board IPO, we can tell you where you stand and what it will take.
Talk to our IPO Advisory team for readiness planning, or our IPO Consultancy team to run the listing end to end.
Last updated:
Information is compiled from exchange notices and the company’s offer document. It is for general information only and is not investment advice or a recommendation to apply. Read the prospectus before investing.